A pyrazine-derived DIPEPTIDYL-PEPTIDASE IV INHIBITOR and HYPOGLYCEMIC AGENT that increases the levels of the INCRETIN hormones GLUCAGON-LIKE PEPTIDE-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). It is used in the treatment of TYPE 2 DIABETES.
Sitagliptin has been studied across 15 research domains including 🔥 Metabolic, 🧬 Hormones, ❤️ Cardiovascular, 🫘 Kidney, 🫁 Liver & Detox. The primary research focus is 🔥 Metabolic with 95% of studies addressing this area.
The following compounds share molecular targets with Sitagliptin, based on binding affinity data from BindingDB and ChEMBL. Sorted by shared target overlap.
This evidence profile for Sitagliptin is generated deterministically from 990 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.
Data source: PubMed/MEDLINE (NLM). Corpus version: current. Patent pending (EVE-PAT-2026-001). © 2026 Organiq Sweden AB.